# Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)

> **NCT03303339** · PHASE1,PHASE2 · COMPLETED · sponsor: **Cardiff Oncology** · enrollment: 72 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Onvansertib
- **DRUG:** Cytarabine
- **DRUG:** Decitabine

## Key facts

- **NCT ID:** NCT03303339
- **Lead sponsor:** Cardiff Oncology
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-11-17
- **Primary completion:** 2021-11-17
- **Final completion:** 2021-11-17
- **Target enrollment:** 72 (ACTUAL)
- **Last updated:** 2023-02-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03303339

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03303339, "Onvansertib in Combination With Either Low-dose Cytarabine or Decitabine in Adult Patients With Acute Myeloid Leukemia (AML)". Retrieved via AI Analytics 2026-07-06 from https://api.ai-analytics.org/clinical/NCT03303339. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*